Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.

@article{Mazires2016LungCP,
  title={Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.},
  author={Julien Mazi{\`e}res and Fabrice Barl{\'e}si and Thomas Filleron and Benjamin Besse and Isabelle Monnet and Mich{\'e}le Beau-Faller and Solange Peters and Eric Dansin and Martin Fr{\"u}h and Miklos Pless and Rafael Rosell and Marie Wislez and Pierre Fournel and V. Westeel and Federico Cappuzzo and Antoine Cortot and Denis L Moro-Sibilot and Julie D Milia and Oliver Gautschi},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2016},
  volume={27 2},
  pages={281-6}
}
BACKGROUND HER2 mutations have been identified as oncogenic drivers in lung cancers and are found in 1-2% of lung adenocarcinomas. There is, to date, no standard of care for these patients. We thus aim to study the therapeutic outcomes of patients harboring HER2 mutations and establish the efficacy of various drug regimens. PATIENTS AND METHODS This retrospective cohort study in European centers assessed patients with advanced non-small-cell lung cancer (NSCLC), a known HER2 exon-20 insertion… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 12 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2015
View 1 Excerpt

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2015
View 1 Excerpt

Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2015
View 2 Excerpts

Neratinib (N) with our without temsirolimus (TEM) in patients (pts) with non-small cell lung cancer (NSCLC) carrying HER2 somatic mutations: an international randomized phase II study

B Besse, J Soria, B Yao
2014
View 3 Excerpts

Biomarkers (BM) France: results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts)

F Barlesi, H Blons, M Beau-Faller
J Clin Oncol • 2013
View 1 Excerpt

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2013
View 4 Excerpts

Similar Papers

Loading similar papers…